. "approved"@en . . . "210589-09-6"@en . . . "For the treatment of mucopolysaccharidosis"@en . . "Laronidase"@en . . . . . . "1.5-3.6 hrs"@en . . " "@en . . . . . "Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites."@en . . . "Humans and other mammals"@en . "Alpha-L-iduronidase precursor"@en . . . "# Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009 Jan;123(1):229-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19117887 # Landry Y, Gies JP: Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008 Feb;22(1):1-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18251718"@en . . "Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate."@en . .